| Financial Highlights | Financial Review | | Management’s Report | Audit Committee’s Report | | Independent Auditors’ Report | Financial Statements | | Notes to Financial Statements | | Directors, Committees, and Officers | | Corporate and Shareholder Information |

	Financial Review (Section 2 of 5) Pfizer Inc and Subsidiary Companies
	On This Page: | Total Revenues by Geographic Area | Changes in Geographic Total Revenues by Business Segment | Product Developments |
	Total Revenues by Geographic Area Changes in Geographic Total Revenues by Business Segment     % Change in Total Revenues   U.S.   International   97/96 96/95   97/96 96/95  Health Care   15 18   6 10  Animal Health   26 (8)   0 5  Consumer Health Care   6 22   9 4  Consolidated   16 16   5 9  Revenues were in excess of $10 million in each of 44 countries outside the U.S. in 1997. The U.S. was the only country to contribute more than 10% to total revenues. Product Developments We continue to invest in R&D to provide future sources of revenue through the development of new products as well as additional uses for existing products. Following are certain significant regulatory actions by and filings pending with the U.S. Food and Drug Administration (FDA): 1997 FDA Approvals Product Indication(s) Date Approved  Trovan Respiratory, surgical, urological, skin   and sexually transmitted infections December 1997  Zoloft Obsessive-compulsive disorder in   children 6 to 17 years of age October 1997  Zoloft Panic Disorder July 1997  Unasyn  Skin infections in children 1 year and older February 1997  Zithromax Pneumonia and pelvic   inflammatory disease January 1997  Pending New Drug Applications (NDAs) Product Indication(s) Date Filed  Zeldox Psychotic disorders —   intramuscular dosage form December 1997  Viagra Erectile dysfunction (impotence) September 1997  Zyrtec Allergies in children 2 to 5   years of age May 1997  Zeldox Psychotic disorders —   oral dosage form March 1997  The FDA notified us in October that Viagra is receiving priority review. Anticipated developments of new products and additional uses for existing products include: • Norvasc – Studies are being conducted to confirm the effectiveness of using Norvasc in the treatment of patients with congestive heart failure attributable to causes other than impaired blood flow to the heart. • Zithromax – We are conducting clinical programs to support a new use for Zithromax in decreasing cardiovascular risk in patients with atherosclerosis (a process in which fatty substances deposit within blood vessels) caused by a certain infection. • Zoloft – We are pursuing clinical programs to develop an oral liquid dosage form and to demonstrate Zoloft’s effectiveness in treating post-traumatic stress disorder (PTSD) as well as other disorders. Filings with the FDA for Zoloft oral liquid and the PTSD indication are expected during 1998. • Tikosyn (dofetilide) – for the treatment of a heart rhythm disorder — Regulatory filings are planned for the first quarter of 1998. • eletriptan – for the treatment of migraine headaches — Regulatory filings are planned for the third quarter of 1998. • droloxifene – for the prevention and treatment of osteoporosis, as well as for the prevention of breast cancer and the treatment of atherosclerosis • Alond (zopolrestat) – for the treatment of nervous system, kidney and cardiovascular disorders related to diabetes • voriconazole – for the treatment of fungal infections • darifenacin – for the treatment of irritable bowel syndrome and urinary urge incontinence Thirteen new chemical entities are in mid- or advanced-stage development or under regulatory review and 55 other compounds are in early-stage development.

	Advisory Information for Investors
	Copyright © 1997, 1998 Pfizer Inc All rights reserved.